Results 1 to 10 of about 100,097 (115)

Lower In‐Hospital Mortality With Beta‐Blocker Use at Admission in Patients With Acute Decompensated Heart Failure

Journal of the American Heart Association, 2021
Background It remains unclear whether beta‐blocker use at hospital admission is associated with better in‐hospital outcomes in patients with acute decompensated heart failure.
Moritake Iguchi, Yusuke Yoshikawa
exaly   +3 more sources

Impact of Beta‐Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Population‐Based Cohort Study

Journal of the American Heart Association, 2017
BackgroundRelevant clinical studies have been small and have not convincingly demonstrated whether the perioperative initiation of beta‐blockers should be considered in patients with diabetes mellitus undergoing noncardiac surgery.
Ray-Jade Chen
exaly   +3 more sources

An Update on the Use of Molecularly Imprinted Polymers in Beta-Blocker Drug Analysis as a Selective Separation Method in Biological and Environmental Analysis

Molecules, 2022
Beta-blockers are antihypertensive drugs and can be abused by athletes in some sport competitions; it is therefore necessary to monitor beta-blocker levels in biological samples.
Aliya Nur Hasanah, Mutakin Mutakin, Ike Susanti   +2 more
exaly   +3 more sources

Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia [PDF]

Annals of Hematology
Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for patients with acute myeloid leukemia (AML) through an immune-mediated graft-versus-leukemia effect, but relapse is common. Studies in solid tumors have shown that adrenergic stress
Johanna Werk, David Baden, Inna Shaforostova, Jan-Henrik Mikesch, Christian Reicherts, Julia Marx, Georg Lenz, Christoph Schliemann, Matthias Stelljes, Alexander Pohlmann   +9 more
doaj   +2 more sources

The Beta‐Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants [PDF]

Clinical and Translational Science
Previous pharmacogenetic findings for beta‐blocker pharmacodynamic candidate genes (ADRB1, ADRB2, ADRA2C, GRK4, and GRK5) have been inconsistent. Therefore, the purpose of this study was to determine whether interactions of pharmacodynamic variants with ...
Jasmine A. Luzum, Shana D. R. Littleton, Ana I. Lopez‐Medina, Bin Liu, Ruicong She, David E. Lanfear   +5 more
doaj   +2 more sources

The Association of Beta-Blocker Use and Bone Mineral Density Level in Hemodialysis Patients: A Cross-Sectional Study

Medicina, 2023
Background and Objectives: Osteoporosis results in increasing morbidity and mortality in hemodialysis patients. The medication for treatment has been limited.
Suthiya Anumas, Saranya Thitisuriyarax, Pichaya Tantiyavarong, Waroot Pholsawatchai, Pattharawin Pattharanitima   +4 more
doaj   +1 more source

A Clinical-Epidemiological Study on Beta-Blocker Poisonings Based on the Type of Drug Overdose

Journal of Toxicology, 2023
Background. Beta‐blockers carry a high risk of potentially causing fatal poisoning if overdosed. We aimed to assess the clinical and epidemiological characteristics of patients with beta-blocker poisoning. Methods.
Nastaran Eizadi-Mood, Mahtab Adib, Arman Otroshi, Gholamali Dorooshi, Rokhsareh Meamar   +4 more
doaj   +1 more source

Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study

Swiss Medical Weekly, 2020
BACKGROUND The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI).
Christel Bruggmann, Stéphane Fournier, Alice Panchaud, Olivier Muller, Farshid Sadeghipour, Pierre Voirol   +5 more
doaj   +1 more source

Impact of beta‐blocker use on the long‐term outcomes of heart failure patients with chronic obstructive pulmonary disease

ESC Heart Failure, 2021
Aims The number of patients with both chronic obstructive pulmonary disease (COPD) and heart failure (HF) is increasing in Asia, and these conditions often coexist.
Yoshiaki Kubota, Wan Ting Tay, Tiew‐Hwa Katherine Teng, Kuniya Asai, Takashi Noda, Kengo Kusano, Atsushi Suzuki, Nobuhisa Hagiwara, Shinji Hisatake, Takanori Ikeda, Ryobun Yasuoka, Takashi Kurita, Wataru Shimizu, ASIAN‐HF Executive Committee   +13 more
doaj   +1 more source

Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm

ESC Heart Failure, 2023
Aims Beta‐blockers are proven to improve survival among patients with heart failure with reduced ejection fraction. Their efficacy in patients with heart failure with reduced ejection fraction and pacemaker devices has not been demonstrated.
Andrew S. Perry, Aldo P. Maggioni, Luigi Tavazzi, Wayne C. Levy   +3 more
doaj   +1 more source